Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Lexicon Pharmaceuticals Inc (LXRX) Common Stock USD0.001 144A

Sell:$3.46 Buy:$3.47 Change: $0.04 (1.14%)
NASDAQ:0.05%
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$3.46
Buy:$3.47
Change: $0.04 (1.14%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$3.46
Buy:$3.47
Change: $0.04 (1.14%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Contact details

Address:
8800 Technology Forest Pl
THE WOODLANDS
77381-1160
United States
Telephone:
+1 (281) 8633000
Website:
www.lexpharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LXRX
ISIN:
US5288723027
Market cap:
$373.01 million
Shares in issue:
106.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Raymond Debbane
    Independent Chairman of the Board
  • Lonnel Coats
    President, Chief Executive Officer, Director
  • Jeffrey Wade
    Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
  • Pablo Lapuerta
    Executive Vice President, Chief Medical Officer
  • Alan Main
    Executive Vice President, Commercial Supply Operations
  • Alexander Santini
    Executive Vice President, Chief Commercial Officer
  • Praveen Tyle
    Executive Vice President - Research and Development
  • James Tessmer
    Vice President - Finance & Accounting

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.